Literature DB >> 923185

Amitriptyline plasma levels and clinical response in primary depression.

D J Kupfer, I Hanin, D G Spiker, T Grau, P Coble.   

Abstract

Sixteen patients with primary depression were treated for 4 wk with amitriptyline. After clinical diagnoses were determined, patients entered a double-blind protocol (amitriptyline or placebo) and their clinical status was determined with the Hamilton Depression Rating Scale by raters blind to the drug type, its dosage and plasma levels. Amitriptyline (AT) and nortriptyline (NT) plasma levels were assayed twice weekly by gas chromatography-mass spectrometry. In the 16 patients, a negative correlation between the Hamilton Score and the mean total tricyclic level (p less than 0.01), as well as with individual plasma levels, was found at the end of the treatment period. When the group was divided into clinical responders and nonresponders, the mean total tricyclic (AT + NT) levels discriminated the two groups by day 12 (p less than 0.001) as well as at the end of the protocol (day 26, 88% of the patients were classified correctly if an arbitrary level of 200 ng/ml total tricyclic plasma level was chosen). These results strongly suggest the presence of a positive correlation between plasma levels and clinical improvement in patients with primary depression.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 923185     DOI: 10.1002/cpt1977226904

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  22 in total

1.  Imipramine and EEG sleep in children with depressive symptoms.

Authors:  D J Kupfer; P Coble; J Kane; T Petti; C K Conners
Journal:  Psychopharmacology (Berl)       Date:  1979-01-31       Impact factor: 4.530

2.  Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline.

Authors:  S Vandel; B Vandel; M Sandoz; G Allers; P Bechtel; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953

3.  Antidepressants in the general hospital.

Authors:  A J Gelenberg
Journal:  Can Med Assoc J       Date:  1979-06-09       Impact factor: 8.262

Review 4.  Discrepancies between pharmacokinetic studies of amitriptyline.

Authors:  P Schulz; P Dick; T F Blaschke; L Hollister
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

Review 5.  Clinical relevance of pharmacokinetics.

Authors:  G Tognoni; C Bellantuono; M Bonati; M D'Incalci; M Gerna; R Latini; M Mandelli; M G Porro; E Riva
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

Review 6.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 7.  Current antidepressant drugs: their clinical use.

Authors:  L E Hollister
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

8.  Norepinephrine and serotonin metabolism and clinical response to combined imipramine and amitriptyline therapy in depression.

Authors:  V Palaniappun; V Ramachandran; O Somasundaram
Journal:  Indian J Psychiatry       Date:  1991-07       Impact factor: 1.759

9.  Relationship between the plasma concentration of clomipramine and desmethylclomipramine in depressive patients and the clinical response.

Authors:  B Vandel; S Vandel; J M Jounet; G Allers; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Relationship between plasma desipramine levels and clinical outcome for RDC major depressive inpatients.

Authors:  G M Simpson; E H Pi; E Abdelmalek; J L Boyd; R S Carroll; T B Cooper; A Miller
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.